BI 655130 ( DrugBank: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
37	膿疱性乾癬（汎発型）	23
96	クローン病	19
97	潰瘍性大腸炎	33

37. 膿疱性乾癬（汎発型）

臨床試験数 : 74 / 薬物数 : 53 - (DrugBank : 20) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 101

diseases per page:

Showing 1 to 10 of 23 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003080-56-ES (EUCTR)	07/02/2022	14/12/2021	A 5-year study to test BI 655130in patients with GeneralizedPustular Psoriasis who took part in prev ...	An open-label, long term extension study to assess the safety andefficacy of BI 655130treatment in p ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim España S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2	United States;Philippines;Taiwan;Greece;Thailand;Spain;Ukraine;Russian Federation;Chile;Israel;Colom ...
2	JPRN-jRCT2041210087	01/11/2021	20/10/2021	A 5-year study to test BI 655130in patients with Generalized Pustular Psoriasis who took part in pre ...	An open-label, long term extension study to assess the safety and efficacy of BI 655130treatment in ...	Generalized Pustular Psoriasis (GPP)	Drug: BI 655130(Spesolimab) / Solution for infusion Drug: BI 655130(Spesolimab) / Solution for inject ...	Yamada Nobuko	NULL	Recruiting	>= 12age old	<= 75age old	Both	4	Phase 2	Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgi ...
3	EUCTR2018-003080-56-BG (EUCTR)	08/09/2021	30/07/2021	A 5-year study to test BI 655130in patients with GeneralizedPustular Psoriasis who took part in prev ...	An open-label, long term extension study to assess the safety andefficacy of BI 655130treatment in p ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...
4	EUCTR2018-003081-14-HR (EUCTR)	26/08/2021	03/12/2021	A study to test whether BI 655130(Spesolimab) prevents flare-ups in patients with Generalized Pustul ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Russian Federation;Chile;Israel;Colom ...
5	EUCTR2018-003081-14-BG (EUCTR)	17/05/2021	14/04/2021	A study to test whether BI 655130(Spesolimab) prevents flare-ups in patients with Generalized Pustul ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...
6	EUCTR2018-003081-14-PL (EUCTR)	24/09/2020	01/06/2020	A study to test whether BI 655130(Spesolimab) prevents flare-ups in patients with Generalized Pustul ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...
7	JPRN-JapicCTI-205387	03/8/2020	23/07/2020	A study to test whether BI 655130(Spesolimab) prevents flare-ups in patients with Generalized Pustul ...	Effisayil(TM) 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase I ...	Generalized Pustular Psoriasis (GPP)	Intervention name : spesolimab INN of the intervention : spesolimab Dosage And administration of the i ...	Boehringer Ingelheim	NULL	complete	12	75	BOTH	120	Phase 2	Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa
8	NCT04399837 (ClinicalTrials.gov)	June 4, 2020	20/5/2020	A Study to Test Whether BI 655130(Spesolimab) Prevents Flare-ups in Patients With Generalized Pustul ...	Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb ...	Generalized Pustular Psoriasis	Drug: Spesolimab;Drug: Placebo	Boehringer Ingelheim	NULL	Active, not recruiting	12 Years	75 Years	All	123	Phase 2	United States;Argentina;Belgium;Bulgaria;Chile;China;Croatia;France;Germany;Greece;Italy;Japan;Korea ...
9	EUCTR2018-003081-14-DE (EUCTR)	16/04/2020	16/12/2019	A study to test whether BI 655130(Spesolimab) prevents flare-ups in patients with Generalized Pustul ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim Pharma GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...
10	EUCTR2018-003081-14-IT (EUCTR)	16/03/2020	15/06/2021	A study to test whether BI 655130(Spesolimab) prevents flare-ups inpatients with Generalized Pustula ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Name: Spesolimab Product Code: [BI 655130] INN or Proposed INN: Spesolimab Other descriptive na ...	BOEHRINGER-INGELHEIM ITALIA S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	98	Phase 2	United States;Taiwan;Greece;Spain;Thailand;Russian Federation;Chile;Italy;Vietnam;France;Malaysia;Au ...

First Previous1 2 3Next Last

先頭へ

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

diseases per page:

Showing 1 to 10 of 19 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-005770-99-NO (EUCTR)	20/01/2022	23/09/2021	A study to test whether spesolimab helps people with Crohn’s disease who have symptoms of bowel obst ...	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab ( ...	Fibrostenotic Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Croh ...	Product Code: BI 655130 INN or Proposed INN: SPESOLIMAB	Boehringer Ingelheim Norway KS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	United States;Portugal;Serbia;Taiwan;Hong Kong;Spain;Ireland;Israel;Switzerland;Italy;France;Denmark ...
2	EUCTR2020-005770-99-IT (EUCTR)	24/11/2021	28/09/2021	A study to test whether spesolimab helps people with Crohn's disease whohave symptoms of bowel obstr ...	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trialto evaluate spesolimab (B ...	Fibrostenotic Crohn's Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Croh ...	Product Name: BI 655130 Product Code: [BI 655130] INN or Proposed INN: SPESOLIMAB	BOEHRINGER-INGELHEIM ITALIA S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Serbia;United States;Portugal;Taiwan;Hong Kong;Spain;Ireland;Israel;Switzerland;Italy;France;Aruba;A ...
3	EUCTR2020-005770-99-NL (EUCTR)	12/11/2021	05/08/2021	A study to test whether spesolimab helps people with Crohn’s disease who have symptoms of bowel obst ...	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab ( ...	Fibrostenotic Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Croh ...	Product Code: BI 655130 INN or Proposed INN: SPESOLIMAB	Boehringer Ingelheim	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	United States;Serbia;Portugal;Taiwan;Hong Kong;Spain;Ireland;Israel;Italy;Switzerland;France;Denmark ...
4	EUCTR2020-005770-99-IE (EUCTR)	09/11/2021	30/07/2021	A study to test whether spesolimab helps people with Crohn’s disease who have symptoms of bowel obst ...	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab ( ...	Fibrostenotic Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Croh ...	Product Code: BI 655130 INN or Proposed INN: SPESOLIMAB	Boehringer Ingelheim Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	United States;Serbia;Portugal;Taiwan;Hong Kong;Spain;Ireland;Israel;Italy;Switzerland;France;Denmark ...
5	NCT05013385 (ClinicalTrials.gov)	November 9, 2021	13/8/2021	A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obst ...	Multi-center, Double-blind, Randomized, Placebo-controlled, Phase IIa Trial to Evaluate Spesolimab ( ...	Fibrostenotic Crohn´s Disease	Drug: Spesolimab;Drug: Placebo	Boehringer Ingelheim	NULL	Recruiting	18 Years	75 Years	All	100	Phase 2	Austria;Belgium;Canada;Germany;Korea, Republic of;Netherlands;Norway;Sweden
6	EUCTR2020-005770-99-SE (EUCTR)	20/10/2021	02/09/2021	A study to test whether spesolimab helps people with Crohn’s disease who have symptoms of bowel obst ...	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab ( ...	Fibrostenotic Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Croh ...	Product Code: BI 655130 INN or Proposed INN: SPESOLIMAB	Boehringer Ingelheim AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	United States;Portugal;Serbia;Taiwan;Hong Kong;Spain;Ireland;Israel;Switzerland;Italy;France;Denmark ...
7	EUCTR2020-005770-99-DK (EUCTR)	22/09/2021	20/08/2021	A study to test whether spesolimab helps people with Crohn’s disease who have symptoms of bowel obst ...	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab ( ...	Fibrostenotic Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Croh ...	Product Code: BI 655130 INN or Proposed INN: SPESOLIMAB	Boehringer Ingelheim B.V	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	United States;Portugal;Serbia;Taiwan;Hong Kong;Spain;Ireland;Israel;Switzerland;Italy;France;Austral ...
8	EUCTR2019-001673-93-ES (EUCTR)	23/04/2021	09/02/2021	A study to test long-term treatment with spesolimab in patients with fistulising Crohn’s disease who ...	An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s d ...	Crohns disease MedDRA version: 20.0;Level: LLT;Classification code 10011408;Term: Crohns disease agg ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Hungary;Belgium;Spain;Denmark;Austria;Netherlands;Germany;Korea, Republic of
9	EUCTR2019-001673-93-BE (EUCTR)	19/01/2021	23/11/2020	A study to test long-term treatment with spesolimab in patients with fistulising Crohn’s disease who ...	An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s d ...	Crohns disease MedDRA version: 20.0;Level: LLT;Classification code 10011408;Term: Crohns disease agg ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Hungary;Spain;Belgium;Denmark;Austria;Netherlands;Germany;Korea, Republic of
10	EUCTR2017-003090-34-DK (EUCTR)	12/11/2020	15/06/2020	A study testing how BI 655130 works in patients with fistulizing Crohn’s Disease	Mechanism of Action and Clinical Effect of BI 655130in Patients with fistulizing Crohn’s Disease - B ...	Fistulizing Crohn’s Disease MedDRA version: 20.0;Level: LLT;Classification code 10075465;Term: Fistu ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 2	Denmark;Netherlands;Germany;Korea, Republic of;Hungary;Spain;Belgium;Austria

First Previous1 2Next Last

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 10 of 33 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-000334-35-NO (EUCTR)	27/11/2019	12/06/2019	BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitis	An open label, long term safety trial of BI 655130treatment in patients with moderate to severely ac ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim Norway KS	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 2	United States;Spain;Austria;Russian Federation;United Kingdom;Italy;Hungary;Canada;Belgium;Poland;No ...
2	EUCTR2018-000334-35-HU (EUCTR)	31/10/2019	06/09/2019	BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitis	An open label, long term safety trial of BI 655130treatment in patients with moderate to severely ac ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANT ...	Boehringer Ingelheim RCV GmbH&Co. KG	NULL	Not Recruiting	Female: yes Male: yes	160	Phase 2	Norway;Netherlands;Germany;Japan;Korea, Republic of;Denmark;Australia;Belgium;Poland;Canada;Czech Re ...
3	EUCTR2017-004230-28-CZ (EUCTR)	04/10/2019	11/07/2019	BI 655130 induction treatment in patients with moderate-to severe ulcerative colitis	A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safet ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANT ...	Boehringer Ingelheim International GmbH	NULL	Not Recruiting	Female: yes Male: yes	550	Phase 2;Phase 3	Korea, Republic of;China;Japan;Germany;Netherlands;Norway;Denmark;Australia;Belgium;Poland;Argentina ...
4	EUCTR2017-004230-28-HU (EUCTR)	06/09/2019	08/07/2019	BI 655130 induction treatment in patients with moderate-to severe ulcerative colitis	A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safet ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Name: spesolimab Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name ...	Boehringer Ingelheim International GmbH	NULL	Not Recruiting	Female: yes Male: yes	550	Phase 2;Phase 3	Spain;Austria;Russian Federation;Israel;United Kingdom;Italy;Hungary;Czech Republic;Mexico;Canada;Ar ...
5	EUCTR2017-004230-28-GR (EUCTR)	01/07/2019	03/05/2019	BI 655130 induction treatment in patients with moderate-to severe ulcerative colitis	A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safet ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANT ...	Boehringer Ingelheim International GmbH	NULL	Not Recruiting	Female: yes Male: yes	550	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Taiwan;Greece;Spain;Austria;Russian Federation;Israel;Italy;United Kingdom;Hungary;Cze ...
6	EUCTR2017-004230-28-DK (EUCTR)	14/06/2019	24/03/2019	BI655130 (SPESOLIMAB) induction treatment in patients with moderate-to-severe ulcerative colitis	A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safet ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Name: spesolimab Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name ...	Boehringer Ingelheim Denmark A/S	NULL	Not Recruiting	Female: yes Male: yes	550	Phase 2;Phase 3	United States;Taiwan;Greece;Spain;Austria;Russian Federation;Israel;Italy;United Kingdom;Hungary;Cze ...
7	EUCTR2018-000334-35-NL (EUCTR)	21/03/2019	29/08/2018	BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitis	An open label, long term safety trial of BI 655130treatment in patients with moderate to severely ac ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANT ...	Boehringer Ingelheim bv Netherlands	NULL	Not Recruiting	Female: yes Male: yes	160	Phase 2	United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;Czech Republic;Hungary;Ca ...
8	EUCTR2018-000334-35-PL (EUCTR)	21/02/2019	07/12/2018	BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitis	An open label, long term safety trial of BI 655130(Spesolimab) treatment in patients with moderate t ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANT ...	Boehringer Ingelheim RCV GmbH&Co. KG	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 2	United States;Czechia;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;Hungary;Canada;Po ...
9	EUCTR2018-000334-35-DE (EUCTR)	12/12/2018	20/08/2018	BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitis	An open label, long term safety trial of BI 655130(Spesolimab) treatment in patients with moderate t ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Product Code: BI 655130 INN or Proposed INN: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANT ...	Boehringer Ingelheim Pharma GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 2	United States;Czechia;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;Hungary;Canada;Po ...
10	EUCTR2018-000334-35-IT (EUCTR)	30/10/2018	17/06/2021	BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitis	An open label, long term safety trial of BI 655130(SPESOLIMAB) treatment in patients with moderate t ...	Moderate-to-severely active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 1 ...	Trade Name: - Product Name: - Product Code: [BI 655130] INN or Proposed INN: Spesolimab Other descriptiv ...	BOEHRINGER-INGELHEIM ITALIA S.P.A.	NULL	Not Recruiting	Female: yes Male: yes	160	Phase 2	Netherlands;Japan;Korea, Republic of;United States;Spain;Austria;Russian Federation;Italy;United Kin ...

First Previous1 2 3 4Next Last

先頭へ